STOCK TITAN

Cumberland Pharmaceuticals (CPIX) 10-K Filings

CPIX NASDAQ

Here are the 10-K annual reports from Cumberland Pharmaceuticals Inc (CPIX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow CPIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPIX filings page.

Rhea-AI Summary

Cumberland Pharmaceuticals Inc. files its annual report describing a specialty pharmaceutical business focused on hospital acute care, gastroenterology and oncology. The company markets seven FDA-approved brands, including Acetadote for acetaminophen poisoning, Caldolor for pain and fever, Kristalose for constipation, Vibativ for serious infections, Sancuso for chemotherapy-induced nausea, Vaprisol for hyponatremia and Talicia for H. pylori.

Cumberland highlights expanding clinical data and labeling for Caldolor, new access agreements for Vibativ, and a U.S. co-commercialization structure for Talicia through Talicia Holdings Inc. Its ifetroban candidate showed positive Phase II results in Duchenne muscular dystrophy cardiomyopathy and is in additional Phase II trials for systemic sclerosis and idiopathic pulmonary fibrosis, supported by orphan, rare pediatric and fast track designations. The company also emphasizes international partnerships, sustainability metrics and disciplined expense management.